NO20032007L - Radiofarmasöytika for diagnostisering av Alzheimers sykdom - Google Patents

Radiofarmasöytika for diagnostisering av Alzheimers sykdom

Info

Publication number
NO20032007L
NO20032007L NO20032007A NO20032007A NO20032007L NO 20032007 L NO20032007 L NO 20032007L NO 20032007 A NO20032007 A NO 20032007A NO 20032007 A NO20032007 A NO 20032007A NO 20032007 L NO20032007 L NO 20032007L
Authority
NO
Norway
Prior art keywords
radiopharmaceuticals
alzheimer
diagnosis
disease
Prior art date
Application number
NO20032007A
Other languages
English (en)
Other versions
NO20032007D0 (no
Inventor
Christoph-Stephan Hilger
Bernd Johannsen
Joerg Steinbach
Peter Maeding
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E Hesselgesser
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20032007D0 publication Critical patent/NO20032007D0/no
Publication of NO20032007L publication Critical patent/NO20032007L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20032007A 2000-11-06 2003-05-05 Radiofarmasöytika for diagnostisering av Alzheimers sykdom NO20032007L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06
PCT/EP2001/012607 WO2002036581A1 (en) 2000-11-06 2001-11-01 Radiopharmaceuticals for diagnosing alzheimer's disease

Publications (2)

Publication Number Publication Date
NO20032007D0 NO20032007D0 (no) 2003-05-05
NO20032007L true NO20032007L (no) 2003-07-02

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032007A NO20032007L (no) 2000-11-06 2003-05-05 Radiofarmasöytika for diagnostisering av Alzheimers sykdom

Country Status (29)

Country Link
US (2) US6676926B2 (no)
EP (1) EP1332138B1 (no)
JP (1) JP4234425B2 (no)
KR (1) KR20030045167A (no)
CN (1) CN1473158A (no)
AR (1) AR035366A1 (no)
AT (1) ATE314354T1 (no)
AU (2) AU1403402A (no)
BG (1) BG107762A (no)
BR (1) BR0115150A (no)
CA (1) CA2424598A1 (no)
DE (1) DE60116365T2 (no)
EA (1) EA006199B1 (no)
EE (1) EE200300216A (no)
HR (1) HRP20030459A2 (no)
HU (1) HUP0301710A3 (no)
IL (1) IL155191A0 (no)
JO (1) JO2207B1 (no)
MX (1) MXPA03003759A (no)
NO (1) NO20032007L (no)
NZ (1) NZ525303A (no)
PE (1) PE20020531A1 (no)
PL (1) PL361631A1 (no)
SK (1) SK287495B6 (no)
TW (1) TWI238820B (no)
UY (1) UY27003A1 (no)
WO (1) WO2002036581A1 (no)
YU (1) YU33203A (no)
ZA (1) ZA200304409B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
EP1438298B1 (en) 2001-10-22 2010-01-27 Pfizer Products Inc. Piperazine derivatives with ccr1 receptor antagonist activity
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
ES2305769T3 (es) * 2003-05-07 2008-11-01 Bayer Schering Pharma Aktiengesellschaft Dispositivo y procedimiento para la fluoracion nucleofila.
CA2552356C (en) * 2004-02-24 2013-11-19 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행
KR101922515B1 (ko) 2006-09-08 2019-02-20 로드아일랜드하스피틀 알코올 유발성 간 질환의 치료, 예방 및 역행
CN101563305A (zh) * 2006-12-21 2009-10-21 哈默史密斯网上成像有限公司 放射性标记方法
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
EP2211911A4 (en) * 2007-10-31 2012-11-14 Alseres Pharmaceuticals Inc METHOD FOR DIAGNOSIS AND MONITORING OF THE TREATMENT OF LEWY BODILY DAMAGE BY EVALUATING THE DOPAMIN TRANSPORTER MIRROR
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
EP2161256A1 (en) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
WO2011041470A2 (en) * 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
US9572787B2 (en) 2011-05-19 2017-02-21 Rhode Island Hospital Inhibition of renal fibrosis
US11623946B2 (en) 2013-12-27 2023-04-11 National University Corporation Tokyo Medical And Dental University Diagnosis methods, diagnostic agents, and therapeutic agents against alzheimer's disease and frontotemporal lobar degeneration, and screening methods for these agents
CA2995847C (en) * 2015-08-28 2024-05-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016239A1 (en) * 1991-03-13 1992-10-01 The Regents Of The University Of Minnesota Radiopharmaceutical agents for the detection of alzheimer's disease
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
AU2680797A (en) * 1996-04-24 1997-11-12 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
AU4157500A (en) 1999-03-26 2000-10-16 Astrazeneca Ab Novel compounds
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
JO2207B1 (en) 2004-10-07
HUP0301710A3 (en) 2007-03-28
TWI238820B (en) 2005-09-01
US6676926B2 (en) 2004-01-13
HRP20030459A2 (en) 2005-04-30
JP2004513123A (ja) 2004-04-30
KR20030045167A (ko) 2003-06-09
BR0115150A (pt) 2003-12-30
AR035366A1 (es) 2004-05-12
HUP0301710A2 (hu) 2003-11-28
NO20032007D0 (no) 2003-05-05
CN1473158A (zh) 2004-02-04
EA006199B1 (ru) 2005-10-27
DE60116365T2 (de) 2006-08-24
PL361631A1 (en) 2004-10-04
EP1332138A1 (en) 2003-08-06
SK5472003A3 (en) 2003-10-07
EE200300216A (et) 2003-08-15
US20020131932A1 (en) 2002-09-19
ZA200304409B (en) 2004-09-06
US6872381B1 (en) 2005-03-29
MXPA03003759A (es) 2003-07-28
YU33203A (sh) 2006-05-25
SK287495B6 (sk) 2010-12-07
WO2002036581A1 (en) 2002-05-10
EP1332138B1 (en) 2005-12-28
AU2002214034B2 (en) 2006-01-05
JP4234425B2 (ja) 2009-03-04
IL155191A0 (en) 2003-11-23
NZ525303A (en) 2004-10-29
BG107762A (bg) 2004-03-31
PE20020531A1 (es) 2002-06-15
CA2424598A1 (en) 2002-05-10
ATE314354T1 (de) 2006-01-15
AU1403402A (en) 2002-05-15
UY27003A1 (es) 2002-07-31
DE60116365D1 (de) 2006-02-02
EA200300507A1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
NO20026199L (no) Forbindelser for behandling av Alzheimers sykdom
NO20032007D0 (no) Radiofarmasöytiske midler for diagnose av Alzheimer's sykdom
PT2264018E (pt) Derivados de tioflavina para uso no diagnóstico da doença de alzheimer
DK1944040T3 (da) Analysefremgangsmåde for Alzheimers sygdom
NO20002380D0 (no) Forbindelser for før-døden diagnose av Alzheimers sykdom og in vivo billeddannelse, samt forhindring av amyloid deponering
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
NO20054640D0 (no) Fremgangsmater for behandling av Parkinsons sykdom
NO944928D0 (no) Fremgangsmåter for inhibering av Alzheimers sykdom
DK1303272T3 (da) Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom
AU2610901A (en) Predictive diagnostic for alzheimer's disease
NO20002686L (no) Forbedring av Peyronies sykdom
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
NO20010953D0 (no) En fremgangsmÕte for behandling av stafylokokkal sykdom
ITMI20030550A1 (it) Macchina ad architettura modulare per l'esecuzione di analisi mediche.
IL175004A0 (en) Quick test for the diagnosis of alzheimer's disease
EP1181550A4 (en) METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20024746L (no) Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom
NO20025790L (no) Syntesefremgangsmåte for fluormetyleringen av alkoholer
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
SI1639139T1 (sl) Postopki za detekcijo Alzheimerjeve bolezni
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease